Natera, Inc. (NASDAQ:NTRA) Chief Financial Officer Michael Burkes recently sold shares of the company as reported in a filing with the Securities and Exchange Commission. The transactions, which were executed as part of a pre-established trading plan, involved the sale of a total of 1,605 shares at prices ranging from $118.81 to $119.19 per share. The total value of these sales amounted to $191,037.
Following these transactions, Burkes holds 72,709 shares of Natera. The sales were conducted under a Rule 10b5-1 trading plan that Burkes adopted on March 14, 2023, allowing executives to sell a predetermined number of shares at a set time, thereby reducing concerns about insider trading.
In other recent news, Natera Inc . has secured a permanent injunction against NeoGenomics (NASDAQ:NEO)' RaDaR assay, following a preliminary injunction granted in December 2023. The court decision supports Natera's claim of patent infringement by NeoGenomics. These developments are part of Natera's broader efforts to protect its intellectual property rights in the genetic testing market.
In earnings and revenue news, Natera has reported a 12% sequential revenue increase from the first quarter and a 58% surge year-over-year. The company is projecting a 40% revenue growth compared to 2023. Analysts from Piper Sandler, TD (TSX:TD) Cowen, and Canaccord Genuity (TSX:CF) have maintained positive stances on Natera, reiterating their price targets and Buy ratings.
In anticipation of the Galaxy study results, Natera's Signatera test is expected to shift oncological discussions as it moves beyond measuring sensitivity to providing insights on overall survival and disease-free survival. Natera's Renasight test has also received an endorsement from the National Kidney Foundation for chronic kidney disease testing. These recent developments underscore Natera's commitment to growth and innovation in the personalized genetic testing and diagnostics space.
InvestingPro Insights
Natera's recent stock performance and financial metrics provide additional context to CFO Michael Burkes' recent share sale. According to InvestingPro data, Natera's stock has shown remarkable strength, with a 201.33% price total return over the past year and an 87.85% return year-to-date. This robust performance aligns with the company's impressive revenue growth, which stood at 46.13% over the last twelve months as of Q2 2024.
Despite the strong top-line growth, InvestingPro Tips highlight that Natera is not currently profitable, with analysts not anticipating profitability this year. This is reflected in the company's negative operating income margin of -23.06% for the last twelve months. However, the company's liquid assets exceed short-term obligations, suggesting a solid near-term financial position.
The stock's volatility, as noted in one of the InvestingPro Tips, is evident in its recent price movements. While the 6-month price total return shows a 28.38% increase, the 1-month return indicates a slight decline of -4.99%. This volatility could be a factor in executive decision-making regarding stock transactions.
Investors considering Natera should note that the company is trading at a high Price/Book multiple of 17.4, which may indicate market optimism about its future prospects. For a more comprehensive analysis, InvestingPro offers 11 additional tips for Natera, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.